Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...

Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

Rezolute, Inc. ( ($RZLT) ) has released its Q2 earnings. Here is a breakdown of the information Rezolute, Inc. presented to its investors.

Rezolute (NASDAQ:RZLT – Get Free Report) ‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a report released on Monday,Benzinga reports.A number of other analysts have ...

Rezolute has a fifty-two week low of $0.98 and a fifty-two week high of $6.19. The firm has a market cap of $284.50 million, a price-to-earnings ratio of -3.87 and a beta of 1.10.

Open-label arm (infant participants DMC approved enrollment of infants into the double-blind portion of the study sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming ...

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved ...